The global human growth hormone treatment and drugs market, currently valued at USD 3.67 billion as of 2023, is on a steady growth trajectory, projected to reach approximately USD 5.26 billion by 2033. With a Compound Annual Growth Rate (CAGR) of 3.7% over the forecast period, this sector is experiencing robust demand, driven primarily by the increasing prevalence of health conditions linked to hGH deficiencies, such as Prader-Willi syndrome, Turner syndrome, and idiopathic short stature (ISS).
Critical Role of Human Growth Hormone: Human growth hormone, also known as somatotropin, is a vital hormone in the human body, responsible for cell regeneration, reproduction, and overall growth stimulation. Deficiencies in hGH, typically due to inadequate synthesis by the pituitary gland, can result in conditions that impact development and growth, often leading to shorter-than-average height and delayed puberty in affected individuals.
Ethical Use Emphasized as Demand Increases: While hGH continues to play a transformative role in addressing these medical needs, its misuse has also surfaced, particularly in the realms of bodybuilding, sports, and among older adults seeking anti-aging benefits. The USFDA has not approved hGH for anti-aging or performance-enhancing purposes and classifies it as a prohibited substance for these non-medical uses. The medical community and industry stakeholders are working diligently to promote the ethical and responsible use of hGH, underscoring its intended applications in healthcare while actively discouraging its misuse.
Industry Growth Drivers: The rising prevalence of hGH deficiency-related conditions across both younger and aging populations is a key factor in market expansion. As awareness of human growth hormone therapy’s benefits grows, more individuals and healthcare providers recognize its potential for enhancing health outcomes. Additionally, increased availability of hGH medications in the market has facilitated access to essential treatments, supporting a growth in revenue for manufacturers and paving the way for advancements in hGH-related healthcare solutions.
Looking Forward: The global hGH market presents a significant opportunity for healthcare stakeholders to collaborate on ensuring that this powerful hormone is utilized responsibly and ethically. Fostering an understanding of hGH’s approved medical uses, while actively preventing its misuse, remains critical in sustaining both market growth and patient trust.
Key Takeaways: Human Growth Hormone Treatment and Drugs Market (2023-2033)
- The global Human Growth Hormone Treatment and Drugs Market is expected to reach a value of around USD 5.26 billion by 2033, reflecting a steady growth at a Compound Annual Growth Rate (CAGR) of 3.7% from 2023 to 2033.
- Growth Drivers:
- Increasing geriatric population with growth in hormone replacement therapies.
- Rising awareness about growth hormone deficiencies and their treatment options.
- Growing investments in research and development (R&D) for novel Human Growth Hormone (HGH) therapies.
- Expanding government initiatives supporting hormone therapies.
- Market Potential: A robust product pipeline, diversification of treatment options, and increasing focus on patient well-being are expected to propel market growth further.
“A healthy product portfolio and extensive Market research investments for the emergence of future growth hormone treatments are projected to propel the sales of human growth hormone treatment & drugs.”
Increased Market Demand: Get In-Depth Analysis and Insights with Our Complete Report!
Competitive Landscape:
Advancements in the development of more efficient chemical formulations are poised to boost the demand for adult human growth hormone injections, benefiting market participants. Leading companies in this sector are actively pursuing mergers and acquisitions to extend their market presence and ramp up the production of human growth hormone injections.
- In February 2022, Pfizer Inc. and OPKO Health, Inc. introduced NGENLA, a once-weekly injection of a long-acting recombinant human growth hormone authorized by the European Commission. This injection is indicated for treating inadequate growth hormone secretion from infancy up to adolescence.
- Additionally, in 2021, the US Food and Drug Administration (FDA) approved Eli Lilly’s product Verzenio (abemaciclib), a CDK4/6 inhibitor for high-risk early breast cancer with HR+ HER2- status.
Key Companies Profiled:
- Ankebio Co. Ltd.
- Eli Lilly and Company
- Emd Serono
- Ferring Pharmaceuticals
- Genentech Inc.
- Gene Science Pharmaceutical Co. Ltd.
- Ipsen, LG Life Sciences
- Merck KGaA
- Novo Nordisk
- Ascendis Pharma
- Pfizer Inc.
Key Market Segments Covered in Human Growth Hormone Treatment and Drugs Market Industry:
By Route of Administration:
- Subcutaneous
- Intramuscular
- Intravenous
- Oral
By Application:
- Growth Hormone Deficiency
- Turner Syndrome
- Idiopathic Short Stature (ISS)
- Prader-Willi Syndrome (PWS)
- Other Applications
By Distribution Channel:
- Hospital Pharmacy
- Specialty Pharmacy
- Retail Pharmacy
- Online Pharmacy
By Region:
- North America
- Latin America
- Europe
- East Asia
- South Asia
- Oceania
- The Middle East and Africa (MEA)
About Future Market Insights (FMI)
Future Market Insights, Inc. (ESOMAR certified, recipient of the Stevie Award, and a member of the Greater New York Chamber of Commerce) offers profound insights into the driving factors that are boosting demand in the market. FMI stands as the leading global provider of market intelligence, advisory services, consulting, and events for the Packaging, Food and Beverage, Consumer Technology, Healthcare, Industrial, and Chemicals markets. With a vast team of over 400 analysts worldwide, FMI provides global, regional, and local expertise on diverse domains and industry trends across more than 110 countries.
Contact Us:
Future Market Insights Inc.
Christiana Corporate, 200 Continental Drive,
Suite 401, Newark, Delaware – 19713, USA
T: +1-347-918-3531
For Sales Enquiries: sales@futuremarketinsights.com
Website: https://www.futuremarketinsights.com
LinkedIn| Twitter| Blogs | YouTube
